| ￥4100 | |
| Z05093 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized BTN2A1&BTN3A1 complex, His & Flag, Human at 1μg/ml (100μl/well) on the plate can bind AntiBTN3A1 Antibody, hFc Tag. Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 30.74 kDa (BTN2A1) and 30.25 kDa (BTN3A1) | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 53-63 kDa (BTN2A1) and 33-38 kDa (BTN3A1) based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | BTN2A1 and BTN3A1 clearly play highly distinct roles in Vγ9Vδ2 T cell detection of P-Ag-exposed cells. BTN2A1&BTN3A1, a protein complex which contains heterodimeric BTN2A1 and BTN3A1 extracellular domains (ECD), is critical to enhance cytotoxic killing by Vγ9Vδ2 T cells. |
| Synonyms | BTN3A1&BTN2A1; BTN2A1&BTN3A1; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
